Insulin Glargine

insulin ; Homo sapiens







1249 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1201 12008682 Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. 2002 Apr 5
1202 12022906 Insulin glargine: a new basal insulin. 2002 Jun 15
1203 12032121 Use of insulin glargine during pregnancy in a type 1 diabetic woman. 2002 Jun 1
1204 12060061 No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. 2002 Jun 7
1205 12145255 Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: a case report. 2002 Aug 1
1206 12150359 Insulin therapy in type 2 diabetes. 2002 Jul-Aug 2
1207 12166545 Insulin glargine (Lantus). 2002 Jul-Aug 17
1208 12166610 Clinical strategies for controlling peaks and valleys: type 1 diabetes. 2002 Jul 3
1209 12324986 Insulin therapy in Europe. 2002 Sep-Oct 2
1210 12324987 An overview of insulin glargine. 2002 Sep-Oct 7
1211 12324990 Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. 2002 Sep-Oct 4
1212 12351503 Insulin glargine in continuous enteric tube feeding. 2002 Oct 1
1213 12391389 Insulin glargine: a new basal insulin analogue. 2002 Nov 2
1214 15765621 Spotlight on insulin glargine in type 1 and 2 diabetes mellitus. 2002 12
1215 11213905 Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes. 2001 Feb 2
1216 11315821 Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. 2001 Apr 4
1217 11367996 [Delayed action insulins. What is the value of insulin glargine in general practice?]. 2001 Apr 19 1
1218 11402927 [Clinical effects and pharmacodynamics of insulin analogs lispro, aspart and glargin]. 2001 May 18 1
1219 11460580 Physiological insulin replacement in type 1 diabetes mellitus. 2001 3
1220 11472271 Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. 2001 Sep 1
1221 11490321 Insulin glargine (Lantus), a new long-acting insulin. 2001 Aug 6 4
1222 11553198 Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. 2001 Aug 7
1223 11577797 Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. 2001 12
1224 11703429 Recent advances in treatment of youth with Type 1 diabetes: better care through technology. 2001 Nov 3
1225 11712396 [Recent trends of development of rapid-acting and long-acting human insulin analogues--its biological characteristics and clinical availability]. 2001 Nov 3
1226 11727406 Insulin therapy in type 2 diabetes. 2001 Dec 1
1227 11739448 Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. 2001 Dec 5
1228 11813930 Insulin glargine. 2001 Dec 13
1229 11825324 Insulin glargine: the first clinically useful extended-action insulin analogue. 2001 Nov 14
1230 11910975 [Present and future of insulin therapy in type 2 diabetic patients]. 2001 Nov 1
1231 12643106 New aspects of insulin therapy in type 1 and type 2 diabetes. 2001 Oct 1
1232 10730548 Insulin glargine. 2000 Feb 8
1233 10834411 Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. 2000 May 2
1234 10834423 Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. 2000 May 9
1235 10834424 Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. 2000 May 4
1236 10841002 Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. 2000 Jun 7
1237 10866053 Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. 2000 Jun 3
1238 10932964 Insulin analogues and management of diabetes mellitus. 2000 Jun 2
1239 10937510 Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. 2000 Aug 5
1240 10937511 Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. 2000 Aug 12
1241 10981882 Insulin glargine. 2000 Aug 5 1
1242 11092290 A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. 2000 Nov 9
1243 11094649 Insulin glargine. 2000 Nov 1 1
1244 11118018 Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. 2000 Dec 4
1245 11130552 Safety of insulin glargine. 2000 Dec 9 1
1246 11225967 Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine. 2000 Dec 2
1247 16049868 Insulin glargine (Aventis Pharma). 2000 Sep 14
1248 10820651 Insulin glargine. Glargine, HOE 71GT15, HOE 71GT80, HOE 901. 1999 Aug 1
1249 15992080 Insulin glargine: the first clinically useful extended-acting insulin in half a century? 1999 Mar 9